Teaming up for biomarker future. Many problems still hinder the use of biomarkers in clinical practice, but new public-private partnerships could improve the situation

EMBO Reports

Volumn 12, Issue 6, 2011, Pages 500-504

  Rinaldi, Andrea ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; COMPLEMENT FACTOR H; MICRORNA; RNA; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CARDIOVASCULAR RISK; CEREBROSPINAL FLUID; CLINICAL PRACTICE; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; EXTRACELLULAR FLUID; HEALTH CARE; INSULIN DEPENDENT DIABETES MELLITUS; NATIONAL HEALTH ORGANIZATION; NEUROIMAGING; PRIORITY JOURNAL; PRODUCTIVITY; PUBLIC-PRIVATE PARTNERSHIP; SAFETY; SEPSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; PREVENTIVE MEDICINE; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 79957975787     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/embor.2011.90     Document Type: Article

References (19)

1. Hye A et al (2006) proteome-based plasma biomarkers for alzheimer's disease. Brain 129: 3042-3050 (Pubitemid 44684524)
2. Kurian SM et al (2011) identification of blood biomarkers for psychosis using convergent functional genomics. Mol Psychiatry 16: 37-58
3. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, Tsuang MT, Salomon DR, Nurnberger Ji JR, Niculescu aB (2009) identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 14: 156-174
4. Mischak H et al (2010) recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2: 46ps42
5. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-arrastia R, Texas alzheimers research consortium (2010) A serum protein-based algorithm for the detection of alzheimer disease. Arch Neurol 67: 1077-1081
6. OEcD (2010) Biomarkers and targeted therapies. paris, France: Organization for Economic cooperation and Development. http://www.oecd.org/ document/48/0,3746,en- 2649-34537-39405168-1-1-1-1,00.html
7. Olson S, Robinson S, Giffin R (2009) accelerating the development of biomarkers for drug safety: workshop summary. Washington, DC, USa: National academies press
8. Patel SD, Le-Niculescu H, Koller DL, Green SD, Lahiri DK, McMahon FJ, Nurnberger Ji JR, Niculescu aB 3rd (2010) coming to grips with complex disorders: genetic risk prediction in bipolar disorder using panels of genes identified through convergent functional genomics. Am J Med Genet B Neuropsychiatr Genet 153B: 850-877
9. Ptolemy AS, Rifai N (2010) What is a biomarker? research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scand J Clin Lab Invest 70: 6-14
10. Ray S et al (2007) Classification and prediction of clinical alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359-1362 (Pubitemid 350073592)
11. Wagner JA et al (2010) The Biomarkers consortium: practice and pitfalls of open-source precompetitive collaboration. Clin Pharmacol Ther 87: 539-542
12. Alkhalaf A et al (2010) Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE 5: e13421
13. Anderson NL (2010) the clinical plasma proteome: A survey of clinical assays for proteins in plasma and serum. Clin Chem 56: 177-185
14. Anon (2010) Biomarkers on a roll. Nat Biotechnol 28: 431
15. BBc (2011) New system uses brain scans to spot early alzheimer's. 7 Mar. http://www.bbc.co.uk/ news/health-12653306
16. D'alessandra Y et al (2010) Circulating microrNas are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31: 2765-2773
17. EMEa (2009) Final conclusions on the pilot joint EMEa/FDa VXDS experience on qualification of nephrotoxicity biomarkers. London, uK: European Medicines agency http://www.ema.europa.eu/docs/en-gB/ document-library/regulatory-and- procedural- guideline/2009/10/Wc500004205.pdf
18. Gold L et al (2010) aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5: e15004
19. Goodsaid FM, Mendrick DL (2010) Translational medicine and the value of biomarker qualification. Sci Transl Med 2: 47ps44